Mulders PF - Search Results

1

Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma.

Gilles R, de Geus-Oei LF, Mulders PF, Oyen WJ. Gilles R, et al. Among authors: mulders pf. World J Urol. 2013 Aug;31(4):841-6. doi: 10.1007/s00345-011-0723-y. Epub 2011 Jul 8. World J Urol. 2013. PMID: 21739122 Free PMC article.

2

Tumor heterogeneity as prognostic factor in patients with low-stage (T1-3N0M0) renal-cell carcinoma.

van der Poel HG, Mulders PF, Oosterhof GO, Schaafsma HE, Hendriks JC, Schalken JA, Debruyne FM. van der Poel HG, et al. Among authors: mulders pf. Investig Urol (Berl). 1994;5:60-5. Investig Urol (Berl). 1994. PMID: 7719322 No abstract available.

3

The role of adjuvant immunotherapy in renal cell carcinoma.

Mulders PF, De Mulder PH. Mulders PF, et al. Curr Urol Rep. 2002 Feb;3(1):44-9. doi: 10.1007/s11934-002-0010-y. Curr Urol Rep. 2002. PMID: 12084219 Review.

4

Re: Clinical role of f-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.

Steffens MG, Mulders PF, Brouwers AH, Oyen WJ. Steffens MG, et al. Among authors: mulders pf. J Urol. 2002 Nov;168(5):2127-8. doi: 10.1016/S0022-5347(05)64320-0. J Urol. 2002. PMID: 12394731 No abstract available.

5

Immunotherapy for renal cell carcinoma.

Bleumer I, Oosterwijk E, De Mulder P, Mulders PF. Bleumer I, et al. Among authors: mulders pf. Eur Urol. 2003 Jul;44(1):65-75. doi: 10.1016/s0302-2838(03)00191-x. Eur Urol. 2003. PMID: 12814677 Review.

6

Targeting of adenovirus to human renal cell carcinoma cells.

Jongmans W, van den Oudenalder K, Tiemessen DM, Molkenboer J, Willemsen R, Mulders PF, Oosterwijk E. Jongmans W, et al. Among authors: mulders pf. Urology. 2003 Sep;62(3):559-65. doi: 10.1016/s0090-4295(03)00378-9. Urology. 2003. PMID: 12946777

7

Tumor antigens and markers in renal cell carcinoma.

Mulders P, Bleumer I, Oosterwijk E. Mulders P, et al. Urol Clin North Am. 2003 Aug;30(3):455-65. doi: 10.1016/s0094-0143(03)00024-7. Urol Clin North Am. 2003. PMID: 12953748 Review.

8

Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.

Brouwers AH, Buijs WC, Oosterwijk E, Boerman OC, Mala C, De Mulder PH, Corstens FH, Mulders PF, Oyen WJ. Brouwers AH, et al. Among authors: mulders pf. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3953S-60S. Clin Cancer Res. 2003. PMID: 14506194

9

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.

Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S, De Mulder P, Mulders PF, Beck J. Bleumer I, et al. Among authors: mulders pf. Br J Cancer. 2004 Mar 8;90(5):985-90. doi: 10.1038/sj.bjc.6601617. Br J Cancer. 2004. PMID: 14997194 Free PMC article. Clinical Trial.

10

[Paraneoplastic syndromes in three patients with renal cell carcinoma].

Steffens MG, de Mulder PH, Mulders PF. Steffens MG, et al. Among authors: mulders pf. Ned Tijdschr Geneeskd. 2004 Mar 6;148(10):487-92. Ned Tijdschr Geneeskd. 2004. PMID: 15042897 Dutch.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

246 results

Search Page